BACKGROUND: Experimental studies suggest that deferoxamine (DFO) limits the generation of reactive oxygen species by chelating redox-active iron and thereby may reduce ischemia-reperfusion injury and myocardial infarct (MI) size. We investigated whether DFO administered before reperfusion by primary percutaneous coronary intervention (PPCI) would ameliorate oxidative stress and MI size. METHODS AND RESULTS: We randomly assigned 60 patients with ST-elevation-MI to receive anintravenous bolus of DFO (500 mg) immediately before PPCI followed by a 12-hour infusion (50 mg/kg of body weight) (n=28) or normal saline bolus and infusion (placebo group, n=32). MI size was measured by contrast-enhanced cardiac MRI (CMRI; day 3±1), creatine kinase and troponin I area-under-the-curve, and severity of wall motion abnormality on echocardiography. Clinical follow-up including repeat CMRI and echocardiography were performed at 3 months (100±17 days). Oxidative stress was assessed by plasma F(2)-isoprostane levels. DFO and placebo groups were well balanced with respect to baseline characteristics, symptom- and door-to-balloon times, pre-PPCI coronary patency, and infarct-related artery location. Serum iron levels were decreased with DFO treatment after PPCI compared with placebo (3.0±2.5 versus 12.6±5.5 μmol/L, P<0.0001), which persisted until the end of the infusion. In DFO-treated patients, there was a significant reduction in plasma F(2)-isoprostane levels immediately after PPCI (2878±1461 versus 2213±579 pmol/L, P=0.04). However, there was no difference in CMRI-determined infarct size (DFO, 17.4±10.8%, versus placebo, 18.6±10.2%; P=0.73), myocardial salvage index at 3 days or at 3 months, or the area-under-the-curve for creatine kinase or troponin I. CONCLUSIONS: Adjunctive DFO treatment after the onset of ischemia and continued periprocedurally ameliorates oxidative stress without limiting infarct size. CLINICAL TRIAL REGISTRATION: URL: http://www.anzctr.org.au/. Unique identifier: ACTRN12608000308392.
RCT Entities:
BACKGROUND: Experimental studies suggest that deferoxamine (DFO) limits the generation of reactive oxygen species by chelating redox-active iron and thereby may reduce ischemia-reperfusion injury and myocardial infarct (MI) size. We investigated whether DFO administered before reperfusion by primary percutaneous coronary intervention (PPCI) would ameliorate oxidative stress and MI size. METHODS AND RESULTS: We randomly assigned 60 patients with ST-elevation-MI to receive an intravenous bolus of DFO (500 mg) immediately before PPCI followed by a 12-hour infusion (50 mg/kg of body weight) (n=28) or normal saline bolus and infusion (placebo group, n=32). MI size was measured by contrast-enhanced cardiac MRI (CMRI; day 3±1), creatine kinase and troponin I area-under-the-curve, and severity of wall motion abnormality on echocardiography. Clinical follow-up including repeat CMRI and echocardiography were performed at 3 months (100±17 days). Oxidative stress was assessed by plasma F(2)-isoprostane levels. DFO and placebo groups were well balanced with respect to baseline characteristics, symptom- and door-to-balloon times, pre-PPCI coronary patency, and infarct-related artery location. Serum iron levels were decreased with DFO treatment after PPCI compared with placebo (3.0±2.5 versus 12.6±5.5 μmol/L, P<0.0001), which persisted until the end of the infusion. In DFO-treated patients, there was a significant reduction in plasma F(2)-isoprostane levels immediately after PPCI (2878±1461 versus 2213±579 pmol/L, P=0.04). However, there was no difference in CMRI-determined infarct size (DFO, 17.4±10.8%, versus placebo, 18.6±10.2%; P=0.73), myocardial salvage index at 3 days or at 3 months, or the area-under-the-curve for creatine kinase or troponin I. CONCLUSIONS: Adjunctive DFO treatment after the onset of ischemia and continued periprocedurally ameliorates oxidative stress without limiting infarct size. CLINICAL TRIAL REGISTRATION: URL: http://www.anzctr.org.au/. Unique identifier: ACTRN12608000308392.
Authors: Sarah V Ekeløf; Natalie L Halladin; Svend E Jensen; Tomas Zaremba; Jens Aarøe; Benedict Kjærgaard; Carsten W Simonsen; Jacob Rosenberg; Ismail Gögenur Journal: Heart Vessels Date: 2014-10-16 Impact factor: 2.037
Authors: Yuichi Baba; Jason K Higa; Briana K Shimada; Kate M Horiuchi; Tomohiro Suhara; Motoi Kobayashi; Jonathan D Woo; Hiroko Aoyagi; Karra S Marh; Hiroaki Kitaoka; Takashi Matsui Journal: Am J Physiol Heart Circ Physiol Date: 2017-11-10 Impact factor: 4.733
Authors: Avinash Kali; Ivan Cokic; Richard Tang; Alice Dohnalkova; Libor Kovarik; Hsin-Jung Yang; Andreas Kumar; Frank S Prato; John C Wood; David Underhill; Eduardo Marbán; Rohan Dharmakumar Journal: Circ Cardiovasc Imaging Date: 2016-11 Impact factor: 7.792
Authors: Dominik Duscher; Evgenios Neofytou; Victor W Wong; Zeshaan N Maan; Robert C Rennert; Mohammed Inayathullah; Michael Januszyk; Melanie Rodrigues; Andrey V Malkovskiy; Arnetha J Whitmore; Graham G Walmsley; Michael G Galvez; Alexander J Whittam; Michael Brownlee; Jayakumar Rajadas; Geoffrey C Gurtner Journal: Proc Natl Acad Sci U S A Date: 2014-12-22 Impact factor: 11.205